Last updated on May 2018

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

Brief description of study

The purpose of this study is to determine the efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration.

Clinical Study Identifier: NCT02611778

Contact Investigators or Research Sites near you

Start Over

Frank G. Holz, Prof. Dr.

University of Bonn, Department of Ophthalmology
Bonn, Germany